Hodges Capital Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Hodges Capital Management’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,854	Closed	-$213K	–	249
2021 Q1	$213K	Buy	+8,854	New	+$206K	0.03%	206
2020 Q1	–	Sell	-7,654	Closed	-$202K	–	227
2019 Q4	$202K	Buy	+7,654	New	+$179K	0.03%	202
2019 Q3	–	Sell	-7,654	Closed	-$235K	–	235
2019 Q2	$235K	Buy	+7,654	New	+$161K	0.03%	194
2018 Q4	–	Sell	-7,354	Closed	-$385K	–	260
2018 Q3	$385K	Hold	7,354	–	–	0.03%	204
2018 Q2	$320K	Hold	7,354	–	–	0.02%	213
2018 Q1	$272K	Sell	7,354 -7,355	-50%	-$196K	0.02%	220
2017 Q4	$292K	Buy	+14,709	New	+$316K	0.02%	218

Other funds holding GTHX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hodges Capital Management's GTHX Position: Q2 2021 in Review

Hodges Capital Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2021, closing a stake of 8,854 shares — an estimated $213K sold.

Hodges Capital Management first reported a position in GTHX in Q4 2017 and held it in 7 quarters. The position peaked at $385K in Q3 2018. 114 funds tracked by Wall St. Rank hold GTHX as of Q2 2021.

Hodges Capital Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Hodges Capital Management sold 8,854 G1 Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $213K.
Hodges Capital Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
Hodges Capital Management's G1 Therapeutics, Inc. Common Stock position peaked at $385K in Q3 2018.
114 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Hodges Capital Management's 13F filing for Q2 2021, filed 6 Jul 2021.